The Medicare number everyone is quoting is $296.05. Almost nobody will pay it.

What is actually ending. The Part D Premium Stabilization Demonstration, established in 2024, will be discontinued at the end of calendar year 2026. CMS's stated reason is that Part D plan sponsors now have "sufficient experience under the redesigned Part D benefit" to price their own bids, and that ending the demonstration returns the programme "to operating under traditional market conditions in CY 2027."

Note the word doing the work: demonstration. Not a benefit, not an entitlement — a temporary programme with a defined life.

What it was for. The Inflation Reduction Act substantially redesigned the Part D benefit. Redesign creates uncertainty, and uncertain insurers price defensively, which would have meant premium spikes for stand-alone drug plans while the market found its footing. The demonstration was a cushion for that transition. It reduced average stand-alone plan premiums by about $26 a month in 2025 and about $16 a month in 2026, capped allowable premium increases at $50, and cut the base premium by $10. Across 2025 and 2026 it cost roughly $9.8 billion.

Two years, a specific purpose, a scheduled end. It did what it was built to do.

Now the number. CMS has set the 2027 national average monthly bid amount at $296.05, up roughly 24%. That figure has travelled widely, often shorn of its name, and it is being read as a premium. It is not.

The bid amount is an enrolment-weighted average of what plans bid to provide the benefit, and it is an input to the formula that determines how much of the cost the federal government subsidises. What a beneficiary pays is a different figure: the base beneficiary premium for 2027 is $41.33.

The gap between $296.05 and $41.33 is not a discount or an error. It is the federal subsidy doing exactly what Part D was designed to do — the government pays the large majority of the cost, and the beneficiary premium is a fraction of the bid. Quoting the bid amount as though it were a bill describes a programme that does not exist.

What genuinely changes. Stand-alone drug plans will set 2027 premiums without the demonstration's support, and the constraints that came with it — including the $50 cap on increases — go with it. Some beneficiaries in stand-alone plans should expect higher premiums than they would otherwise have faced.

The honest limit on that statement is that plan-specific premiums for 2027 are not yet known. They are set by individual plans and published ahead of open enrolment. Anyone quoting a precise figure for what beneficiaries will pay next year is estimating.

What does not change. This is the part most reporting omits, and it is most of the programme:

- The out-of-pocket cap on prescription drug spending, established by the IRA, continues unchanged

- The redesigned Part D benefit itself is unaffected — the demonstration supported the transition, it was not the benefit

- Insulin cost limits and vaccine coverage continue

- Extra Help, the low-income subsidy, continues

The demonstration was a scaffold around a building. Removing scaffolding is not demolition, and it is worth knowing which one you are looking at.

Why the framing matters. There is a real story here about cost pressure on older Americans, and it deserves accurate numbers. Describing a scheduled two-year programme's expiry as a benefit cut misdirects attention toward a decision that was always going to happen, and away from the harder question — whether the redesigned benefit prices sustainably once the cushion is gone. That question is genuinely open. It is not answered by $296.05.

Where legitimate concern sits. KFF has noted that the decision could mean larger premium increases for some beneficiaries next year, and that is the correct register: some, could, and specifically those in stand-alone prescription drug plans rather than all Medicare enrollees. A 24% rise in the average bid does indicate that plans are pricing the redesigned benefit as more expensive to provide, and that pressure has to surface somewhere — in premiums, in federal subsidy costs, or in plan design.

What happens next, and the dates are fixed. Plans file and publish 2027 premiums ahead of open enrolment this autumn, which converts every estimate in circulation into a fact. Enrolment shifts between stand-alone plans and Medicare Advantage drug coverage will show whether beneficiaries move in response. And the number that would actually justify alarm is not the bid amount — it is the spread of published plan premiums when they land, against the $41.33 base.